Abnormal Liver Function Induced by Space-Occupying Lesions Is Associated with Unfavorable Oncologic Outcome in Patients with Colorectal Cancer Liver Metastases
Table 2
Colorectal liver metastases, treatment, and survival characteristics depending on normal/abnormal values of liver function tests.
Clinicopathological features
Normal
Abnormal AP
Abnormal γGT
Abnormal LDH
Abnormal ALT and/or AST
No. patients
257
92
204
160
155
Largest tumor size (cm)
≤5
153
21
77
54
58
>5
20
27
<0.001
53
<0.001
49
<0.001
40
<0.001
Number of liver metastases
1
65
13
37
26
20
>1
166
73
0.017
157
0.029
128
0.011
125
0.001
Hepatectomy
Wedge resection
14
1
2
2
2
Segmentectomy
2
0
1
0
1
Hemihepatectomy
0
0
1
0
0
No
241
91
0.049
200
0.026
158
0.015
152
0.044
Type of ablation
RFA
26
11
34
16
26
Cryotherapy
6
0
1
1
1
No
225
81
0.901
169
0.155
143
0.573
88
0.007
Chemotherapy
Yes
81
34
71
57
64
No
176
58
0.341
133
0.456
103
0.386
91
0.044
MoAbs
Yes
2
1
2
0
0
No
255
91
0.863
202
0.816
160
0.263
155
0.271
HAIP placement
Yes
4
2
4
4
3
No
253
90
0.696
200
0.741
156
0.495
152
0.773
Radiotherapy
Yes
7
0
2
1
1
No
250
92
0.110
202
0.179
159
0.129
154
0.139
Progression-free survival (months)
≤12
225
72
165
129
118
>12
27
17
0.042
33
0.065
27
0.056
34
0.002
Overall survival
median (months)
18
10
14
9
12
Hazard ratio (95% CI)
-
0.57 (0.33–0.70)
0.68 (0.51–0.83)
0.50 (0.32–0.56)
0.62 (0.40–0.76)
value (log-rank)
-
<0.001
<0.001
<0.001
<0.001
Survival rate (%) (95% CI)
3 months
96.6 (93.3–98.3)
83.5 (72.8–90.3)
85.7 (79.5–90.0)
84.8 (77.6–89.8)
88.7 (81.9–93.0)
6 months
89.6 (84.9–92.9)
64.2 (51.6–74.2)
71.7 (64.3–77.9)
65.8 (57.1–73.2)
78.3 (70.2–84.5)
12 months
65.4 (58.5–71.5)
42.5 (30.1–54.3)
51.5 (43.3–59.0)
36.7 (28.1–45.2)
55.7 (46.2–64.3)
24 months
31.0 (24.0–38.2)
20.0 (9.8–32.8)
17.8 (11.2–25.8)
8.0 (3.6–14.6)
16.8 (9.1–26.5)
with normal group. RFA, radiofrequency ablation; HAIP, hepatic artery infusion pump; MoAbs, monoclonal antibodies; CI, confidence intervals.
